SUBSCRIBE
SUBSCRIBE
News   Policy

Merck KGaA Met US Regulators on Cladribine in January But No Timetable on Resubmitting MS Drug

February 1, 2010 | 
1 min read
Bookmark and Share

Reuters -- Germany's Merck KGaA met with U.S. regulators in January about the approval process for its multiple sclerosis pill cladribine but does not yet have a clear timetable for resubmitting the drug.
Regulatory
MORE ON THIS TOPIC
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
 · 
2 min read
 · 
Jef Akst
Illustration showing businessman trying to create his own road
FDA
Compass vows to press on with FDA application despite new trial request
September 22, 2026
 · 
3 min read
 · 
Annalee Armstrong
FDA
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026
 · 
1 min read
 · 
Jef Akst
Creative concept of leadership and innovation with a glowing blue light bulb leading paper planes. Symbol of advanced technology, AI-driven strategy, and visionary direction in a digital future.
Regulatory
FDA opens Operation TrialBlazer for applications, hoping to reshore early trials
September 15, 2026
 · 
1 min read
 · 
Heather McKenzie